Xencor presents Phase 1 dose selection data for XmAb819, a potential first-of-its-kind ENPP3 x CD3 Bispecific T-Cell Engager, in development for patients with advanced clear cell renal cell carcinoma and ENPP3+ tumors. Company announcement - F.

Xencor presents Phase 1 dose selection data for XmAb819, a potential first-of-its-kind ENPP3 x CD3 Bispecific T-Cell Engager, in development for patients with advanced clear cell renal cell carcinoma and ENPP3+ tumors. Company announcement - F.